Riskpilot← Back to searchSign inGet full accessPHARMALAB ApS
APSDissolvedCVR 33058101Postvej 1Manufacture of other general-purpose machinery n.e.c. · NACE 2829Est. 2010— employees
Revenue 2023
DKK -42K
-594% vs 2022
EBITDA margin
100.0%
-594% vs 2022
Equity ratio
-65.1%
Financial strength
Net profit 2023
DKK -32K
-88% vs 2022
| Revenue | DKK -42K | -594% |
| EBITDA | DKK -42K | -594% |
| Net profit | DKK -32K | -88% |
| Total assets | DKK 165K | -83% |
| Equity | DKK -108K | -41% |
| Employees | — | — |
Legal name
PHARMALAB ApS
CVR number
33058101
Legal form
Anpartsselskab
NACE code
2829 · Manufacture of other general-purpose machinery n.e.c.
Founded
2. juli 2010
Share capital
DKK 279.770
Employees
—
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren
Address
Postvej 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -23 | -151 | -57 | -135 | -198 | 8 | -138 | -28 | -10 | -17 | 9 | -42 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -23 | -151 | -57 | -135 | -198 | 8 | -668 | -28 | -10 | -17 | 9 | -42 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -6 | -13 | -13 |
| EBIT | -23 | -151 | -57 | -135 | -198 | 8 | -668 | -28 | -10 | -24 | -4 | -55 |
| Net financials | -1 | -1 | 0 | -1 | -17 | -30 | 1.004 | -1 | -0 | -0 | -13 | 22 |
| Profit before tax | -12 | -150 | -57 | -136 | -216 | -22 | 336 | -29 | -10 | -24 | -17 | -33 |
| Tax | 6 | -34 | -11 | 12 | -0 | -0 | 50 | -6 | -2 | -0 | -0 | -1 |
| Net profit | -18 | -116 | -46 | -148 | -216 | -22 | 286 | -23 | -8 | -24 | -17 | -32 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 41 | 62 | 113 | 174 | 241 | 251 | 16 | 31 | 17 | 196 | 999 | 165 |
| Equity | 27 | -9 | 94 | -54 | -269 | -291 | -5 | -27 | -35 | -59 | -76 | -108 |
| Long-term debt | 0 | -52 | -62 | -91 | 0 | 0 | 0 | -75 | -73 | 0 | 0 | 0 |
| Short-term debt | 15 | 71 | 18 | 228 | 511 | 542 | 21 | 59 | 53 | 255 | 1.075 | 273 |
| Total debt | 15 | 71 | 18 | 228 | 511 | 542 | 21 | 59 | 53 | 255 | 1.075 | 273 |
EBITDA margin
-4225600.0%
This company
15.8%
Market median
-26744404% vs market
20122023
Equity ratio
-65.1%
This company
38.2%
Market median
-270% vs market
20122023
Return on equity
-3150500.0%
This company
18.4%
Market median
-17122383% vs market
20122023
Net profit margin
-3150500.0%
This company
8.1%
Market median
-38895162% vs market
20122023
Asset turnover
-0.26×
This company
1.12×
Market median
-123% vs market
20122023
Debt / equity
2.54×
This company
0.62×
Market median
-310% vs market
20122023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LO Management | Management | 2012 | — | — |
LM Management | Management | 2021 | — | — |
JB Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2010 | — | — | |
| Chairman | 2010 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
JBN ApS | Company | 50.0% | 50.0% | 2021 |
L.O.V.K.O HOLDING ApS | Company | 33.3% | 33.3% | 2014 |
| Individual | 5.0% | 5.0% | 2014 | |
ROTECH ApS | Company | 33.3% | 33.3% | 2014 |
| Individual | 10.0% | 10.0% | 2014 | |
LMCR Holding ApS | Company | 50.0% | 50.0% | 2021 |
HOUG TØMRER- OG SNEDKERFIRMA ApS | Company | 10.0% | 10.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHARMALAB ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Olofsson | Management | 0 companies |
| Lars Muhlig | Management | 0 companies |
| Jan Bojsen | Management | 0 companies |
| Jens Glavind | Chairman | 0 companies |
| Geo Allan Østergaard | Chairman | 0 companies |
| Ole Houg Larsen | Board of Directors | 0 companies |
| John Askholm | Chairman | 0 companies |